- Home
- GRRR vs BCYC Comparison
GRRR vs BCYC Comparison
Compare GRRR & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRRR
- BCYC
- Stock Information
- Founded
- GRRR 2001
- BCYC 2009
- Country
- GRRR United Kingdom
- BCYC United Kingdom
- Employees
- GRRR 142
- BCYC N/A
- Industry
- GRRR Computer Software: Prepackaged Software
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- GRRR Technology
- BCYC Health Care
- Exchange
- GRRR Nasdaq
- BCYC Nasdaq
- Market Cap
- GRRR 478.4M
- BCYC 701.7M
- IPO Year
- GRRR N/A
- BCYC 2019
- Fundamental
- Price
- GRRR $25.91
- BCYC $9.63
- Analyst Decision
- GRRR Buy
- BCYC Buy
- Analyst Count
- GRRR 1
- BCYC 8
- Target Price
- GRRR $18.00
- BCYC $29.14
- AVG Volume (30 Days)
- GRRR 5.5M
- BCYC 247.7K
- Earning Date
- GRRR 04-03-2025
- BCYC 05-01-2025
- Dividend Yield
- GRRR N/A
- BCYC N/A
- EPS Growth
- GRRR N/A
- BCYC N/A
- EPS
- GRRR 2.28
- BCYC N/A
- Revenue
- GRRR $78,940,347.00
- BCYC $35,275,000.00
- Revenue This Year
- GRRR $12.29
- BCYC N/A
- Revenue Next Year
- GRRR $38.43
- BCYC $18.29
- P/E Ratio
- GRRR $11.36
- BCYC N/A
- Revenue Growth
- GRRR 424.97
- BCYC 30.76
- 52 Week Low
- GRRR $2.09
- BCYC $9.58
- 52 Week High
- GRRR $44.15
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- GRRR 49.78
- BCYC 31.44
- Support Level
- GRRR $23.56
- BCYC $9.58
- Resistance Level
- GRRR $44.15
- BCYC $10.84
- Average True Range (ATR)
- GRRR 6.46
- BCYC 0.65
- MACD
- GRRR -0.97
- BCYC -0.00
- Stochastic Oscillator
- GRRR 25.87
- BCYC 2.24
About GRRR Gorilla Technology Group Inc.
Gorilla Technology Group Inc is primarily engaged in providing information, software, and data processing services. It is a provider of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology (OT) security solutions and services. Its reportable segments are video IoT and security convergence and Other segments.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.